Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
Open Access
- 1 October 1999
- journal article
- clinical trial
- Published by Wiley
- Vol. 48 (4), 564-572
- https://doi.org/10.1046/j.1365-2125.1999.00053.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevanceBritish Journal of Clinical Pharmacology, 1999
- Efficacy and safety of tolterodine in patients with detrusor instability: a dose‐ranging studyBritish Journal of Urology, 1998
- Antimuscarinic Potency and Bladder Selectivity of PNU‐200577, a Major Metabolite of TolterodineBasic & Clinical Pharmacology & Toxicology, 1997
- Drug Interactions with Grapefruit JuiceClinical Pharmacokinetics, 1997
- Tolterodine – a new bladder-selective antimuscarinic agentEuropean Journal of Pharmacology, 1997
- Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluationWorld Journal of Urology, 1997
- Polymorphic Drug OxidationCNS Drugs, 1996
- Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardiaEuropean Journal of Clinical Pharmacology, 1993
- Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1986
- Effect of ketoconazole on hepatic oxidative drug metabolismClinical Pharmacology & Therapeutics, 1985